<DOC>
	<DOCNO>NCT00467649</DOCNO>
	<brief_summary>This randomize , open label , parallel group , multicenter study . There two phase study . Phase 1 ( Baseline Week 24 ) compare efficacy safety regimens basal insulin intensify either Symlin rapid act insulin patient type 2 diabetes either prior regimen insulin less 6 month take less 50 U total insulin per day OR candidate initiation insulin therapy . The purpose Phase 2 ( Week 24 Week 36 ) explore intensification diabetes regimens patient fail achieve HbA1c &lt; =6.5 % Week 24 .</brief_summary>
	<brief_title>A Study Characterize Regimens Basal Insulin Intensified With Either Symlin® Rapid Acting Insulin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Short-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Has clinical diagnosis type 2 diabetes mellitus Has HbA1c &gt; 7.0 % ≤10.0 % Has BMI ≥25 kg/m^2 ≤50 kg/m^2 Has regimen insulin less 6 month take less 50 U total insulin per day , OR pre exist insulin regimen candidate initiation basal insulin therapy Has experience recurrent severe hypoglycemia require assistance past 6 month Requires use drug stimulate gastrointestinal motility Has previously treat Symlin ( participate Symlin clinical study ) Is currently treat follow medication : *Overthecounter antiobesity agent ( include , limited , herbal supplement ) prescription antiobesity agent ( include orlistat [ Xenical® ] sibutramine [ Meridia® ] ) ; *Oral , intravenous , intramuscular systemic steroid oral potent inhale intrapulmonary steroid know high rate systemic absorption ; *Drugs directly affect gastrointestinal motility , include limited : dopamine antagonist ( e.g. , metoclopramide [ Reglan® ] ) , opiates anticholinergic ; chronic ( 10 day within 6month period ) macrolide antibiotic erythromycin new derivative ; *Investigational medication Has history presence following : *Eating disorder ( include anorexia and/or bulimia ) ; *Bariatric surgery ( gastric bypass , gastric banding , gastroplasty ) Is currently enrol weightloss program plan enroll weightloss program termination study Has donate blood within 30 day study start plan donate blood duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Symlin</keyword>
	<keyword>Amylin</keyword>
	<keyword>insulin</keyword>
	<keyword>Humalog</keyword>
	<keyword>Novolog</keyword>
	<keyword>Apidra</keyword>
</DOC>